Table S II.
Analysis of the evolution of the LP of the different generic Paclitaxel medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovador (BMS) | 01/10/2006 | 01/11/1999 | 4.27 | NA | NA | NA |
| Generic 1 (Merck) | 08/11/2007 | 30/05/2007 | 1.87 | 0 | -56% | NA |
| Generic 2 (GP-Pharm) | 09/10/2008 | 05/05/2008 | 1.87 | 0.9 | -56% | 0% |
| Generic 3 (Stragen) | 07/05/2009 | 15/12/2008 | 1.35 | 1.5 | -68% | -28% |
| Generic 4 (Accord) | 29/02/2012 | 27/10/2011 | 1.31 | 4.3 | -69% | -30% |
| Generic 5 (Swan Pond) | 30/06/2012 | 14/02/2012 | 1.31 | 4.6 | -69% | -30% |
| Generic 6 (Fresenius) | 31/07/2012 | 15/10/2010 | 1.31 | 4.7 | -69% | -30% |
| Generic 7 (Cipla) | 31/12/2015 | 09/10/2015 | 1.31 | 8.2 | -69% | -30% |
*1 In the case of the innovative drug, the most recent obtained (October 2006) is taken as LP.
*2 In the case of the innovative drug, the authorized LP at the time of marketing of the first generic is indicated.